Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab
{{output}}
Background: Systemic therapy in lung cancer is mainstay of treatment as most patients present in advanced stages, with rising importance of new immunotherapy agents. ... ...
